AU2011232850B2 - Antibodies against CSF-1R - Google Patents

Antibodies against CSF-1R Download PDF

Info

Publication number
AU2011232850B2
AU2011232850B2 AU2011232850A AU2011232850A AU2011232850B2 AU 2011232850 B2 AU2011232850 B2 AU 2011232850B2 AU 2011232850 A AU2011232850 A AU 2011232850A AU 2011232850 A AU2011232850 A AU 2011232850A AU 2011232850 B2 AU2011232850 B2 AU 2011232850B2
Authority
AU
Australia
Prior art keywords
ser
leu
val
pro
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011232850A
Other languages
English (en)
Other versions
AU2011232850A1 (en
Inventor
Jacqueline Francoise Doody
Yanxia Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone LLC filed Critical ImClone LLC
Publication of AU2011232850A1 publication Critical patent/AU2011232850A1/en
Application granted granted Critical
Publication of AU2011232850B2 publication Critical patent/AU2011232850B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2011232850A 2010-04-01 2011-03-28 Antibodies against CSF-1R Ceased AU2011232850B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31989610P 2010-04-01 2010-04-01
US61/319,896 2010-04-01
PCT/US2011/030148 WO2011123381A1 (en) 2010-04-01 2011-03-28 Antibodies against csf-1r

Publications (2)

Publication Number Publication Date
AU2011232850A1 AU2011232850A1 (en) 2012-09-06
AU2011232850B2 true AU2011232850B2 (en) 2014-06-19

Family

ID=44010222

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011232850A Ceased AU2011232850B2 (en) 2010-04-01 2011-03-28 Antibodies against CSF-1R

Country Status (30)

Country Link
US (1) US8263079B2 (cg-RX-API-DMAC7.html)
EP (2) EP2552966B1 (cg-RX-API-DMAC7.html)
JP (1) JP5767310B2 (cg-RX-API-DMAC7.html)
KR (1) KR101439719B1 (cg-RX-API-DMAC7.html)
CN (1) CN102834414B (cg-RX-API-DMAC7.html)
AR (1) AR080698A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011232850B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012024564A2 (cg-RX-API-DMAC7.html)
CA (1) CA2795081C (cg-RX-API-DMAC7.html)
CY (1) CY1119324T1 (cg-RX-API-DMAC7.html)
DK (1) DK2552966T3 (cg-RX-API-DMAC7.html)
EA (1) EA021600B1 (cg-RX-API-DMAC7.html)
ES (1) ES2640909T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171153T1 (cg-RX-API-DMAC7.html)
HU (1) HUE036379T2 (cg-RX-API-DMAC7.html)
IL (1) IL222222A (cg-RX-API-DMAC7.html)
JO (1) JO3291B1 (cg-RX-API-DMAC7.html)
LT (1) LT2552966T (cg-RX-API-DMAC7.html)
ME (1) ME02806B (cg-RX-API-DMAC7.html)
MX (1) MX2012011234A (cg-RX-API-DMAC7.html)
NZ (1) NZ602621A (cg-RX-API-DMAC7.html)
PL (1) PL2552966T3 (cg-RX-API-DMAC7.html)
PT (1) PT2552966T (cg-RX-API-DMAC7.html)
RS (1) RS56219B1 (cg-RX-API-DMAC7.html)
SG (1) SG183829A1 (cg-RX-API-DMAC7.html)
SI (1) SI2552966T1 (cg-RX-API-DMAC7.html)
TW (1) TWI402078B (cg-RX-API-DMAC7.html)
UA (1) UA111818C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011123381A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201206926B (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105218672A (zh) 2009-12-10 2016-01-06 霍夫曼-拉罗奇有限公司 优先结合人csf1r胞外域4的抗体及其用途
US20160208011A1 (en) 2010-01-28 2016-07-21 The Board Of Trustees Of The Leland Stanford Junior University Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same
US10626399B2 (en) 2010-01-28 2020-04-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cognitive symptoms of an aging-associated impairment by modulating C-C chemokine receptor type 3 (CCR3)
US10487148B2 (en) 2010-01-28 2019-11-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating aging-associated impairments
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN112480256A (zh) 2010-05-04 2021-03-12 戊瑞治疗有限公司 结合csf1r的抗体
US9161968B2 (en) 2011-04-08 2015-10-20 The Board Of Trustees Of The Leland Stanford Junior University Methods of neuroprotection involving macrophage colony stimulating factor receptor agonists
CA2853889A1 (en) 2011-12-15 2013-06-20 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
WO2013119716A1 (en) * 2012-02-06 2013-08-15 Genentech, Inc. Compositions and methods for using csf1r inhibitors
AR090263A1 (es) * 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US20130302322A1 (en) 2012-05-11 2013-11-14 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
BR112015004426A2 (pt) 2012-08-31 2018-08-28 Five Prime Therapeutics, Inc. método para reduzir o nível, tratar uma condição, tratar uma condição inflamatória, tratar distúrbio de cd16+, tratar um respondente inadequado de metotrexate, tratar um respondente inadequado de inibidor de tnf, indentificar um sujeito, predizer responsividade e métodos para tratar uma condição inflamatória
AR095882A1 (es) * 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB201315487D0 (en) 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
AR097584A1 (es) * 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
JP6667438B2 (ja) 2013-12-09 2020-03-18 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 老化に関連する状態を処置する方法及び組成物
US10905779B2 (en) 2013-12-09 2021-02-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for screening human blood products comprising plasma using immunocompromised rodent models
KR102000224B1 (ko) * 2014-02-03 2019-07-16 전대연 스마트 이메일 관리방법
BR112016029460A2 (pt) 2014-06-23 2017-10-24 Five Prime Therapeutics Inc métodos para tratar artrite reumatoide
IL251464B2 (en) 2014-10-29 2023-03-01 Five Prime Therapeutics Inc Combination therapy for cancer
BR112017013111A2 (pt) 2014-12-22 2018-05-15 Five Prime Therapeutics Inc métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
JP6971850B2 (ja) 2015-04-13 2021-11-24 ファイヴ プライム セラピューティクス インク がんの併用療法
MY195000A (en) 2015-05-27 2022-12-30 Ucb Biopharma Sprl Method for the treatment of neurological disease
DK3307296T3 (da) 2015-06-15 2021-12-13 Univ Leland Stanford Junior Timp2 til anvendelse til behandling af aldringsassocierede tilstande
JP6621252B2 (ja) * 2015-06-17 2019-12-18 国立大学法人北海道大学 治療耐性がんに対する治療耐性低減剤
CR20170537A (es) * 2015-06-24 2018-02-20 Hoffmann La Roche Anticuerpos contra csf-1r humano para uso en la inducción de linfocitosis en linfomas o leucemias.
EP3108897A1 (en) 2015-06-24 2016-12-28 F. Hoffmann-La Roche AG Antibodies against human csf-1r for use in inducing lymphocytosis in lymphomas or leukemias
EP3973988A1 (en) 2015-11-04 2022-03-30 Duke University Combination therapy of immunotoxin and checkpoint inhibitor
WO2017085566A1 (en) * 2015-11-20 2017-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for increase/induction of immune responses
US20180291107A1 (en) * 2015-11-24 2018-10-11 Eli Lilly And Company Combination therapy for cancer
MA44309A (fr) * 2015-11-25 2018-10-03 Nogra Pharma Ltd Oligonucléotides antisens il-34 et leurs procédés d'utilisation
US10245285B2 (en) 2016-04-28 2019-04-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression
CN116903741A (zh) 2016-06-20 2023-10-20 科马布有限公司 特异性结合于pd-l1的抗体或其抗原结合片段及其用途
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
AR109770A1 (es) 2016-10-18 2019-01-23 Lilly Co Eli ANTICUERPOS DEL RECEPTOR II DE TGF-b
EA039316B1 (ru) 2016-10-24 2022-01-12 Алкахест, Инк. Фракции плазмы крови в качестве лечения когнитивных расстройств, связанных со старением
CN110072553B (zh) * 2016-12-22 2023-09-15 豪夫迈·罗氏有限公司 在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
WO2018144334A1 (en) 2017-02-02 2018-08-09 Imclone Llc Dosing regimen for anti-csf-1r antibody
WO2018183366A1 (en) 2017-03-28 2018-10-04 Syndax Pharmaceuticals, Inc. Combination therapies of csf-1r or csf-1 antibodies and a t-cell engaging therapy
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
ES2971462T3 (es) 2017-04-26 2024-06-05 Alkahest Inc Pauta posológica para el tratamiento de los trastornos cognitivos con productos de plasma sanguíneo
US11040068B2 (en) 2017-04-26 2021-06-22 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
KR20240042244A (ko) 2017-05-19 2024-04-01 신닥스 파마슈티컬스, 인크. 조합 요법
TWI870011B (zh) 2017-08-25 2025-01-11 美商戊瑞治療有限公司 Ｂ７－ｈ４抗體及其使用方法
CA3073531A1 (en) 2017-09-13 2019-03-21 Five Prime Therapeutics, Inc. Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
JP7348899B2 (ja) * 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
CN111741978A (zh) 2018-02-21 2020-10-02 戊瑞治疗有限公司 B7-h4抗体制剂
GB201803226D0 (en) * 2018-02-28 2018-04-11 Ultrahuman Twelve Ltd CSF1R Binding agents
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
CN112566935B (zh) * 2018-05-23 2024-12-13 百济神州有限公司 抗ox40抗体和使用方法
CN108948200B (zh) * 2018-07-18 2019-05-10 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及其应用
CN108948201B (zh) * 2018-07-18 2019-05-07 博奥信生物技术（南京）有限公司 抗人csf-1r单克隆抗体及应用
CN109096397B (zh) * 2018-07-18 2019-04-16 博奥信生物技术（南京）有限公司 一种抗人csf-1r单克隆抗体及应用
KR20210049106A (ko) * 2018-07-27 2021-05-04 알렉터 엘엘씨 항-siglec-5 항체 및 이의 사용 방법
JP7465272B2 (ja) 2018-09-27 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｃｓｆ１ｒ／ｃｃｒ２多特異性抗体
JP7504090B2 (ja) 2018-10-26 2024-06-21 アルカヘスト，インコーポレイテッド 疼痛、創傷治癒及び術後回復の改善のための血漿及び血漿画分の使用
CN113301960B (zh) 2018-12-13 2025-06-03 财团法人生物技术开发中心 抗人类csf-1r抗体和其用途
ES2984122T3 (es) * 2019-03-05 2024-10-29 Inserm Institut National De La Santeet De La Rech Medicale Biomarcadores para carcinoma de células renales
CN113939539B (zh) * 2019-05-15 2024-06-04 博奥信生物技术（南京）有限公司 结合csf-1r的抗体及其用途
JP2022532837A (ja) * 2019-05-24 2022-07-20 エリクシロン・イミュノセラピューティクス・（ホンコン）・リミテッド 抗ｃｓｆ１ｒ抗体、ｉｌ１０融合タンパク質、及びそれらの使用
CN110499295A (zh) * 2019-09-11 2019-11-26 宝船生物医药科技(上海)有限公司 一种csf-1r报告基因细胞株及其制备方法和应用
WO2021058718A1 (en) 2019-09-26 2021-04-01 Roche Diagnostics Gmbh Anti-csf-1r antibody
CN114929274A (zh) * 2019-10-17 2022-08-19 台湾卫生研究院 琥珀酸作为用于癌症诊断和治疗的生物标记的用途
KR102373965B1 (ko) * 2020-06-05 2022-03-15 (주)지아이이노베이션 Ｉｌ-２ 단백질 및 ｃｄ８０ 단백질을 포함하는 융합단백질을 포함하는 방사선 치료 증진용 약학적 조성물
CN115806626B (zh) * 2022-06-21 2024-02-23 四川大学华西医院 一种基于csf1的嵌合抗原受体免疫细胞制备及其应用
CN121219009A (zh) 2023-05-17 2025-12-26 信达克思制药公司 使用抗集落刺激因子1受体抗体治疗慢性移植物抗宿主病相关的闭塞性细支气管炎综合征的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026303A1 (en) * 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
ES2070172T3 (es) 1988-04-16 1995-06-01 Celltech Ltd Procedimiento para producir proteinas mediante adn recombinante.
JPH0967400A (ja) 1995-08-31 1997-03-11 Toray Ind Inc モノクローナル抗体、該抗体を産生するハイブリドーマ及びその利用
ES2345885T3 (es) * 2002-11-15 2010-10-05 Novartis Vaccines And Diagnostics, Inc. Metodos para prevenir y tratar metastasis de cancer y perdida de hueso asociada con la metastasis de cancer.
AR054233A1 (es) 2005-03-08 2007-06-13 Pharmacia & Upjohn Co Llc Composiciones de anticuerpos igg2
NZ587830A (en) * 2008-03-14 2012-08-31 Transgene Sa Antibody against the colony-stimulating factor-1 receptor (CSF-1R)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009026303A1 (en) * 2007-08-21 2009-02-26 Amgen Inc. Human c-fms antigen binding proteins

Also Published As

Publication number Publication date
EA021600B1 (ru) 2015-07-30
CY1119324T1 (el) 2018-02-14
HUE036379T2 (hu) 2018-07-30
MX2012011234A (es) 2012-11-30
ME02806B (me) 2018-01-20
ES2640909T3 (es) 2017-11-07
EA201270732A1 (ru) 2013-01-30
EP3156419A1 (en) 2017-04-19
PL2552966T3 (pl) 2017-12-29
US20110243947A1 (en) 2011-10-06
KR101439719B1 (ko) 2014-09-12
NZ602621A (en) 2014-02-28
US8263079B2 (en) 2012-09-11
WO2011123381A1 (en) 2011-10-06
CA2795081A1 (en) 2011-10-06
TWI402078B (zh) 2013-07-21
JO3291B1 (ar) 2018-09-16
RS56219B1 (sr) 2017-11-30
HRP20171153T1 (hr) 2017-10-06
AR080698A1 (es) 2012-05-02
UA111818C2 (uk) 2016-06-24
LT2552966T (lt) 2017-10-10
EP2552966B1 (en) 2017-07-05
IL222222A (en) 2016-02-29
DK2552966T3 (en) 2017-08-14
KR20130001258A (ko) 2013-01-03
EP2552966A1 (en) 2013-02-06
AU2011232850A1 (en) 2012-09-06
TW201138824A (en) 2011-11-16
SI2552966T1 (sl) 2017-08-31
SG183829A1 (en) 2012-10-30
BR112012024564A2 (pt) 2016-11-29
IL222222A0 (en) 2012-12-31
CN102834414B (zh) 2014-10-08
JP2013529183A (ja) 2013-07-18
JP5767310B2 (ja) 2015-08-19
CA2795081C (en) 2017-12-05
PT2552966T (pt) 2017-09-29
CN102834414A (zh) 2012-12-19
ZA201206926B (en) 2014-03-26

Similar Documents

Publication Publication Date Title
AU2011232850B2 (en) Antibodies against CSF-1R
JP5068270B2 (ja) 癌を処置するためのｉｌ−１７アンタゴニスト抗体
EP3344658B1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
JP3519415B2 (ja) 抗―Ｆｃαレセプター抗体からなる治療用多重特異的化合物
KR20020000223A (ko) 표피성장인자 수용체 길항제를 사용한 인간 난치성 종양의치료 방법
JP2022514693A (ja) Ｍｕｃ１８に特異的な抗体
US20220411501A1 (en) Anti-cd117 antibodies and methods of use thereof
US20250171547A1 (en) Epha3 directed car-t cells for treatment of tumors
JP5911813B2 (ja) Ｃｄ２０に対するモノクローナル抗体
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
EP4483899A1 (en) Medicine comprising combination of anti-mutant-calr antibody and another drug
EP4410840A1 (en) Bispecific antibody and application thereof
CN109195626B (zh) 结合死亡受体4和死亡受体5的抗体
EA009807B1 (ru) Антитело против igf-i-рецептора
RU2776795C2 (ru) Антитела к белку cd38 и их применение
HK40121119A (en) Medicine comprising combination of anti-mutant-calr antibody and another drug
WO2025122988A2 (en) Engineered antibodies and immunoconjugates and methods of use
JP2021504492A (ja) 癌治療のための組成物および方法
HK1176626B (en) Antibodies against csf-1r
HK1176626A (en) Antibodies against csf-1r

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired